Vitamin D Receptor Activators and Clinical Outcomes in Chronic Kidney Disease

Table 3

Suppression of PTH and effects on calcium and phosphate levels: doxercalciferol versus placebo and doxercalciferol versus paricalcitol.

Author	Year	Study	Outcome 1	Outcome 2
Joist et al. [19]	2006	Crossover study; 𝑛=13 dialysis patients 36-hour study paricalcitol versus doxercalciferol	Clinical suppression of PTH at 36 hours was comparable between treatment arms (63% following paricalcitol therapy and 65% following doxercalciferol therapy).	Serum phosphorus was significantly higher during administration of doxercalciferol (2.12 ± 0.11 mmol/L versus 1.85 ± 0.07 mmol/L).
Frazão et al. [20]	2000	Double-blind, RCT; 𝑛=99 dialysis patients 8-week study	80% of doxercalciferol patients showed a 70% reduction in PTH levels from baseline, and 83% of the doxercalciferol patients met the study PTH targets.	During double-blinded treatment, 3.26% and 0.46% of [Ca] measurements exceeded 11.2 mg/dl with doxercalciferol and placebo, respectively.
Coburn et al. [21]	2004	RCT, 𝑛=55 patients with stage 3 or 4 CKD treated with doxercalciferol versus placebo.	Mean plasma iPTH level decreased by 46% from baseline after 24 weeks of doxercalciferol treatment (𝑃<.001), versus placebo. After 6 weeks, iPTH level decreased with doxercalciferol versus placebo (𝑃<.001).	No significant differences in mean serum calcium or phosphorus between the groups.
Zisman et al. [22]	2005	RCT, 𝑛=27 hemodialysis patients randomized to receive doxercalciferol at either 35, 50, or 65% of the paricalcitol dose for 6 weeks	A conversion factor of 0.57 for the dose of doxercalciferol relative to paricalcitol resulted in equivalent suppression of iPTH	Incidences of hypercalcemia and hyperphosphatemia were similar for all groups